Novel methods for the determination of the angiogenic activity of human tumors

Mattia Barbareschi, Giampietro Gasparini, Luca Morelli, Stefano Forti, Paolo Dalla Palma

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

At present the most used method to quantify tumor angiogenesis in human solid tumors is the count of intratumoral microvessels in the primary lesion. This method requires the use of specific markers to vascular endothelium and of immunohistochemical procedures to visualize microvessels. Several studies have found that intratumoral microvessel density (IMD) determined in the primary tumor is significantly associated with metastasis and prognosis in some solid neoplasia, particularly in operable breast carcinoma. The subjective evaluation of IMD made by two observers at the microscope is rapid and of low cost, but presents some difficulties, mainly the identification of the most vascularized area ("hot-spot") within each tumor. This method can be improved upon to attain a better reproducibility among different pathologists. For example, the use of a multiparametric computerized image analysis system (CIAS) seems to be a promising tool to improve accuracy, feasibility and reproducibility of microvessel counts, although there are still some open technical problems to completely automate its use. Angiogenic activity is the result of a balance between angiogenic stimuli and angio-inhibition. Therefore the determination of angiogenic peptides and/or natural angiogenesis inhibitors in the tumor tissue, serum, or urine of cancer patients seems to be a promising alternative to microvessel counting. At present it is possible to determine the expression of basic fibroblast growth factor (bFGF), vascular endothelial growth factor, and transforming growth factor beta using immunohistochemical methods. Serum and urine levels of bFGF can be assessed using an immunoenzymatic assay. Methods used to assess the expression and levels of urokinase-type plasminogen activator (uPA) or plasminogen activator inhibitor-1 (PAI-1) have also been developed, and correlate with angiogenic activity and prognosis of patients with breast cancer. Finally, some investigational methods to assess angiogenesis in vivo are presented and discussed. Angiogenesis is a very complex phenomenon. Thus it seems reasonable to hypothesize that its assessment by using concurrently several of the available methods may provide more valid, accurate, and comprehensive information on the angiogenic activity of each single tumor. For a reliable and reproducible assessment of angiogenesis for all of the assays, validation procedures and quality control protocols are mandatory.

Original languageEnglish
Pages (from-to)181-192
Number of pages12
JournalBreast Cancer Research and Treatment
Volume36
Issue number2
DOIs
Publication statusPublished - Jan 1995

Fingerprint

Human Activities
Microvessels
Neoplasms
Fibroblast Growth Factor 2
Angiogenic Proteins
Urine
Breast Neoplasms
Angiogenesis Inhibitors
Plasminogen Activator Inhibitor 1
Urokinase-Type Plasminogen Activator
Vascular Endothelium
Serum
Transforming Growth Factor beta
Quality Control
Vascular Endothelial Growth Factor A
Neoplasm Metastasis
Costs and Cost Analysis

Keywords

  • angiogenesis
  • fibroblast growth factors
  • image analysis
  • immunohistochemical assays
  • methods
  • microvessel density
  • plasminogen activator inhibitor (PAI-I)
  • urokinase-type plasminogen activator (uPA)
  • vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Barbareschi, M., Gasparini, G., Morelli, L., Forti, S., & Dalla Palma, P. (1995). Novel methods for the determination of the angiogenic activity of human tumors. Breast Cancer Research and Treatment, 36(2), 181-192. https://doi.org/10.1007/BF00666039

Novel methods for the determination of the angiogenic activity of human tumors. / Barbareschi, Mattia; Gasparini, Giampietro; Morelli, Luca; Forti, Stefano; Dalla Palma, Paolo.

In: Breast Cancer Research and Treatment, Vol. 36, No. 2, 01.1995, p. 181-192.

Research output: Contribution to journalArticle

Barbareschi, M, Gasparini, G, Morelli, L, Forti, S & Dalla Palma, P 1995, 'Novel methods for the determination of the angiogenic activity of human tumors', Breast Cancer Research and Treatment, vol. 36, no. 2, pp. 181-192. https://doi.org/10.1007/BF00666039
Barbareschi, Mattia ; Gasparini, Giampietro ; Morelli, Luca ; Forti, Stefano ; Dalla Palma, Paolo. / Novel methods for the determination of the angiogenic activity of human tumors. In: Breast Cancer Research and Treatment. 1995 ; Vol. 36, No. 2. pp. 181-192.
@article{7e807790372e46928e9cddd139337578,
title = "Novel methods for the determination of the angiogenic activity of human tumors",
abstract = "At present the most used method to quantify tumor angiogenesis in human solid tumors is the count of intratumoral microvessels in the primary lesion. This method requires the use of specific markers to vascular endothelium and of immunohistochemical procedures to visualize microvessels. Several studies have found that intratumoral microvessel density (IMD) determined in the primary tumor is significantly associated with metastasis and prognosis in some solid neoplasia, particularly in operable breast carcinoma. The subjective evaluation of IMD made by two observers at the microscope is rapid and of low cost, but presents some difficulties, mainly the identification of the most vascularized area ({"}hot-spot{"}) within each tumor. This method can be improved upon to attain a better reproducibility among different pathologists. For example, the use of a multiparametric computerized image analysis system (CIAS) seems to be a promising tool to improve accuracy, feasibility and reproducibility of microvessel counts, although there are still some open technical problems to completely automate its use. Angiogenic activity is the result of a balance between angiogenic stimuli and angio-inhibition. Therefore the determination of angiogenic peptides and/or natural angiogenesis inhibitors in the tumor tissue, serum, or urine of cancer patients seems to be a promising alternative to microvessel counting. At present it is possible to determine the expression of basic fibroblast growth factor (bFGF), vascular endothelial growth factor, and transforming growth factor beta using immunohistochemical methods. Serum and urine levels of bFGF can be assessed using an immunoenzymatic assay. Methods used to assess the expression and levels of urokinase-type plasminogen activator (uPA) or plasminogen activator inhibitor-1 (PAI-1) have also been developed, and correlate with angiogenic activity and prognosis of patients with breast cancer. Finally, some investigational methods to assess angiogenesis in vivo are presented and discussed. Angiogenesis is a very complex phenomenon. Thus it seems reasonable to hypothesize that its assessment by using concurrently several of the available methods may provide more valid, accurate, and comprehensive information on the angiogenic activity of each single tumor. For a reliable and reproducible assessment of angiogenesis for all of the assays, validation procedures and quality control protocols are mandatory.",
keywords = "angiogenesis, fibroblast growth factors, image analysis, immunohistochemical assays, methods, microvessel density, plasminogen activator inhibitor (PAI-I), urokinase-type plasminogen activator (uPA), vascular endothelial growth factor",
author = "Mattia Barbareschi and Giampietro Gasparini and Luca Morelli and Stefano Forti and {Dalla Palma}, Paolo",
year = "1995",
month = "1",
doi = "10.1007/BF00666039",
language = "English",
volume = "36",
pages = "181--192",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "2",

}

TY - JOUR

T1 - Novel methods for the determination of the angiogenic activity of human tumors

AU - Barbareschi, Mattia

AU - Gasparini, Giampietro

AU - Morelli, Luca

AU - Forti, Stefano

AU - Dalla Palma, Paolo

PY - 1995/1

Y1 - 1995/1

N2 - At present the most used method to quantify tumor angiogenesis in human solid tumors is the count of intratumoral microvessels in the primary lesion. This method requires the use of specific markers to vascular endothelium and of immunohistochemical procedures to visualize microvessels. Several studies have found that intratumoral microvessel density (IMD) determined in the primary tumor is significantly associated with metastasis and prognosis in some solid neoplasia, particularly in operable breast carcinoma. The subjective evaluation of IMD made by two observers at the microscope is rapid and of low cost, but presents some difficulties, mainly the identification of the most vascularized area ("hot-spot") within each tumor. This method can be improved upon to attain a better reproducibility among different pathologists. For example, the use of a multiparametric computerized image analysis system (CIAS) seems to be a promising tool to improve accuracy, feasibility and reproducibility of microvessel counts, although there are still some open technical problems to completely automate its use. Angiogenic activity is the result of a balance between angiogenic stimuli and angio-inhibition. Therefore the determination of angiogenic peptides and/or natural angiogenesis inhibitors in the tumor tissue, serum, or urine of cancer patients seems to be a promising alternative to microvessel counting. At present it is possible to determine the expression of basic fibroblast growth factor (bFGF), vascular endothelial growth factor, and transforming growth factor beta using immunohistochemical methods. Serum and urine levels of bFGF can be assessed using an immunoenzymatic assay. Methods used to assess the expression and levels of urokinase-type plasminogen activator (uPA) or plasminogen activator inhibitor-1 (PAI-1) have also been developed, and correlate with angiogenic activity and prognosis of patients with breast cancer. Finally, some investigational methods to assess angiogenesis in vivo are presented and discussed. Angiogenesis is a very complex phenomenon. Thus it seems reasonable to hypothesize that its assessment by using concurrently several of the available methods may provide more valid, accurate, and comprehensive information on the angiogenic activity of each single tumor. For a reliable and reproducible assessment of angiogenesis for all of the assays, validation procedures and quality control protocols are mandatory.

AB - At present the most used method to quantify tumor angiogenesis in human solid tumors is the count of intratumoral microvessels in the primary lesion. This method requires the use of specific markers to vascular endothelium and of immunohistochemical procedures to visualize microvessels. Several studies have found that intratumoral microvessel density (IMD) determined in the primary tumor is significantly associated with metastasis and prognosis in some solid neoplasia, particularly in operable breast carcinoma. The subjective evaluation of IMD made by two observers at the microscope is rapid and of low cost, but presents some difficulties, mainly the identification of the most vascularized area ("hot-spot") within each tumor. This method can be improved upon to attain a better reproducibility among different pathologists. For example, the use of a multiparametric computerized image analysis system (CIAS) seems to be a promising tool to improve accuracy, feasibility and reproducibility of microvessel counts, although there are still some open technical problems to completely automate its use. Angiogenic activity is the result of a balance between angiogenic stimuli and angio-inhibition. Therefore the determination of angiogenic peptides and/or natural angiogenesis inhibitors in the tumor tissue, serum, or urine of cancer patients seems to be a promising alternative to microvessel counting. At present it is possible to determine the expression of basic fibroblast growth factor (bFGF), vascular endothelial growth factor, and transforming growth factor beta using immunohistochemical methods. Serum and urine levels of bFGF can be assessed using an immunoenzymatic assay. Methods used to assess the expression and levels of urokinase-type plasminogen activator (uPA) or plasminogen activator inhibitor-1 (PAI-1) have also been developed, and correlate with angiogenic activity and prognosis of patients with breast cancer. Finally, some investigational methods to assess angiogenesis in vivo are presented and discussed. Angiogenesis is a very complex phenomenon. Thus it seems reasonable to hypothesize that its assessment by using concurrently several of the available methods may provide more valid, accurate, and comprehensive information on the angiogenic activity of each single tumor. For a reliable and reproducible assessment of angiogenesis for all of the assays, validation procedures and quality control protocols are mandatory.

KW - angiogenesis

KW - fibroblast growth factors

KW - image analysis

KW - immunohistochemical assays

KW - methods

KW - microvessel density

KW - plasminogen activator inhibitor (PAI-I)

KW - urokinase-type plasminogen activator (uPA)

KW - vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=0029121680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029121680&partnerID=8YFLogxK

U2 - 10.1007/BF00666039

DO - 10.1007/BF00666039

M3 - Article

C2 - 8534866

AN - SCOPUS:0029121680

VL - 36

SP - 181

EP - 192

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -